Why the study?
Does continuing dual antiplatelet therapy beyond 12 months improve ischemic outcomes in patients with acute coronary syndromes after drug-eluting stent placement?
Does continuing dual antiplatelet therapy beyond 12 months improve ischemic outcomes in patients with acute coronary syndromes after drug-eluting stent placement?
Answers are grounded in this paper and cite their sources.
Extending dual antiplatelet therapy beyond 12 months after drug-eluting stent placement reduces ischemic events but increases bleeding risk, suggesting a net benefit in selected populations who tolerate initial therapy.
For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Halkar et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: